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Abstract
Background: Due to the SARS-CoV-2 pandemic, public health interventions have been introduced globally in order to
prevent the spread of the virus and avoid the overload of health care systems, especially for the most severely affected
patients. Scientific studies to date have focused primarily on describing the clinical course of patients, identifying
treatment options and developing vaccines. In Germany, as in many other regions, current tests for SARS-CoV2 are not
conducted on a representative basis and in a longitudinal design. Furthermore, knowledge about the immune status of
the population is lacking. Nonetheless, these data are needed to understand the dynamics of the pandemic and hence to
appropriately design and evaluate interventions. For this purpose, we recently started a prospective population-based
cohort in Munich, Germany, with the aim to develop a better understanding of the state and dynamics of the pandemic.
Methods: In 100 out of 755 randomly selected constituencies, 3000 Munich households are identified via random route
and offered enrollment into the study. All household members are asked to complete a baseline questionnaire and
subjects ≥14 years of age are asked to provide a venous blood sample of ≤3ml for the determination of SARS-CoV-2
IgG/IgA status. The residual plasma and the blood pellet are preserved for later genetic and molecular biological
investigations. For twelve months, each household member is asked to keep a diary of daily symptoms, whereabouts and
contacts via WebApp. If symptoms suggestive for COVID-19 are reported, family members, including children < 14 years,
are offered a pharyngeal swab taken at the Division of Infectious Diseases and Tropical Medicine, LMU University Hospital
Munich, for molecular testing for SARS-CoV-2. In case of severe symptoms, participants will be transferred to a Munich
hospital. For one year, the study teams re-visits the households for blood sampling every six weeks.
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Discussion: With the planned study we will establish a reliable epidemiological tool to improve the understanding of the
spread of SARS-CoV-2 and to better assess the effectiveness of public health measures as well as their socio-economic
effects. This will support policy makers in managing the epidemic based on scientific evidence.
Keywords: COVID-19, Pandemics, Coronavirus infections/epidemiology, Panel study, Enzyme-linked Immunosorbent
assay, Models, economic, Stress, psychological, Socio-economic factors, Spatial analysis, Geographic information systems
Background
Since the first description of the novel coronavirus disease
(COVID-19) in December 2019 in Wuhan, China, the dis-
ease has spread worldwide and classified as a global emer-
gency by the WHO in early 2020 [1]. In Germany, the
first confirmed case of COVID-19 was registered on Janu-
ary 6th 2020 at the Division of Infectious Diseases and
Tropical Medicine, LMU University Hospital Munich [2,
3]. The transmission chains were interrupted by contact
tracing and isolation of the affected persons. However,
due to the return of German tourists from holidays in the
high-risk areas of northern Italy, in connection with a car-
nival celebration in the district of Heinsberg (60 km west
of Cologne), the virus spread to 13 of 16 federal states
within one month [4]. The exponential increase in newly
confirmed cases in Germany reached a total of 155.193
positively tested cases on April 27th 2020 (187 per 100,
000 inhabitants) [4].
Simulations and experiences of other countries suggest
that healthcare systems would be overburdened and
eventually collapse due to a pronounced increase of pa-
tients needing intensive care support if no interventions
were implemented [5–13]. In the absence of vaccinations
and specific treatment options, public health interven-
tions were initiated in Germany, similarly to numerous
other countries comparably affected. The measures in-
clude isolation of confirmed patients, quarantine of their
contacts, use of personal protective equipment, social
distancing (including school closures), and closure of
borders [6, 14]. Prediction models and experiences from
countries like South Korea suggest that combination of
these measures could be effective in combatting the dis-
ease [13, 15–18]. However, past evidence from other epi-
demics was not that convincing with respect to
controlling virus spread by social distancing [19]. It re-
mains unclear how comparable previous viral diseases
outbreaks are to SARS-CoV-2 [20]. While potentially
saving lives and protecting healthcare systems from
breakdown, one has to bear in mind that measures of so-
cial distancing can have a devastating impact on national
and global economies, healthcare systems, incomes of
individuals and families (especially those in precarious
employment conditions), education (which particularly
affects disadvantaged groups) and on health and the psy-
chosocial well-being of populations [20–22]. Devastating
effects seen in high-income societies will likely be much
worse in low and middle income countries [23].
Results of simulation studies existing so far differ con-
siderably. This is partly due to the unknown number of
asymptomatic or minimally symptomatic SARS-CoV-2
carriers, and thus the number of undetected cases [4, 7,
13, 17, 24, 25]. In addition, the number of confirmed
cases depends on access to healthcare, laboratory avail-
ability, and on the criteria applied to select the individ-
uals who should be tested. Therefore, the basic and the
effective reproduction number can only be very roughly
estimated and the hospitalization and mortality rates re-
main to be confirmed. Community cohorts can help to
assess the overall spread of infection in the targeted
population and thus provide more reliable estimates of
the basic and the effective reproduction number. This
will help to evaluate the burden on the healthcare sys-
tem as well as the effectiveness of public health interven-
tions [26].
Methods
Aim of KoCo19 (prospective Covid-19 cohort Munich)
With the community-based household study presented
in this paper, we aim to study the sero-prevalence and
-incidence of SARS-CoV-2 antibodies in a representative
household sample of the Munich population. With this
approach we will provide a constantly updated epi-
demiological instrument that represents the number of
infections that have occurred in the city. The study may
also serve as a pilot for studies in other areas of
Germany and other countries.
The following study questions will be addressed:
1) Baseline visit
 What is the SARS-CoV-2 antibody prevalence in the
Munich general population?
 How many of the initially seropositive individuals in
the baseline-study were previously tested by
pharyngeal swab and nucleic acid amplification
(PCR) (positively or negatively) and/or had symp-
toms suggestive for COVID-19 (yes or no)?
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 What is the distribution of symptom severity in each
of the groups described above?
 How high is the risk of infection for other
household members if one person is infected and
can household risk factors be identified?
 How high is the risk of infection for other
inhabitants of the same apartment building if one
person is infected?
 What are the risk factors for SARS-CoV-2
infections?
2) Follow-up visits
 Is there a change in antibody titers of those who
initially tested positive, which is potentially
necessary to discriminate from cross-reactivity with
other corona viruses?
 How long are SARS-CoV-2 specific antibodies de-
tectable after infections of varying severity?
 How does the spread of the disease develop and
what influence do public health measures have on
the incidence?
 What is the impact of individual behaviour on the
incidence of infection?
 Which risk factors are associated with SARS-CoV-2
incidence?
 What is the socio-economic impact of the pandemic
and the measures to combat it, especially on the em-
ployment situation and psychosocial endpoints?
Setting of KoCo19
Munich, the capital of the Free State of Bavaria, is lo-
cated in the southeast of Germany. Approximately 1.5
million people live here, 9% of these are 75 years and
older [27]. The population density is 50 inhabitants per
ha [27]. There are 70 hospital beds (including 5 intensive
care unit beds) and 13 doctors for every 10,000 inhabi-
tants [27]. After the first 100 cases of SARS-CoV-2 were
reported in Munich by March 12th 2020, the Bavarian
schools and universities were closed on March 16th
2020, initially until May 11 th 2020. Since the same date,
all shops that do not sell the basic needs of the popula-
tion were closed. Starting on March 21th 2020, when
1288 infected individuals were reported in Munich, cur-
fews were implemented [28]. According to these cur-
fews, people are essentially only allowed to leave the
house to go to work, to the doctor, to buy food, for out-
door sport related activities (jogging, walking) or to help
others who are depending on support. A minimum dis-
tance of 1.5 m between individuals must be maintained.
Design of KoCo19
The study design of KoCo19 is a community-based pro-
spective cohort study in randomly selected Munich
households. All members of the selected households
who are eligible and agree to participate (see “Study
population”) are invited to the following parts of the
study:
1. Baseline study (1st household visit): During the
baseline study, personal identifying information is
collected and stored in a database separately from
the remaining questionnaire information. A blood
sample is taken from which sero-prevalences of
SARS-CoV-2 IgG and IgA antibodies are
determined.
After the household visit, participants are asked to
answer an:
a. Online household questionnaire and an
b. Online personal questionnaire.
2. Daily diary: Using a web-based app, participants are
asked to fill out a daily diary on symptoms suggest-
ive of COVID-19 infection, whereabouts, and social
contacts. Additional questions might be included
throughout the follow-up period. If symptoms of
COVID-19 occur, a pharyngeal swab for PCR test-
ing of SARS-CoV-2 is offered at our division.
3. Follow-up household visits: Households are re-
visited every three to six weeks for a new blood
sample in order to estimate the sero-incidence of
SARS-CoV-2 infection. This frequency can be
adapted to the current necessities of estimated pre-
diction models. The follow-ups are currently
planned for up to 12 months.
The study will be terminated if more efficient methods
to assess the course of the epidemic are developed or if
this no longer appears relevant.
KoCo19 study population
For KoCo19, a representative sample of Munich house-
holds (target population) is selected by random walk
door-to-door methodology [29]. For this purpose, 100 of
the 755 Munich constituencies were randomly selected
using R (The R project). In each of these constituencies,
the geographic center is selected as the starting point of
the random route using QGIS. From the address closest
to this starting point, 30 households per constituency
will be included in the study according to a fixed algo-
rithm. In the case of apartment buildings, one household
per floor is selected to investigate possible transmission
within the building.
All household members ≥14 years are invited to par-
ticipate in KoCo19 by donating a maximum of 3 ml of
blood and to be available for further blood tests every
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three to six weeks. Participants are informed about their
SARS-CoV-2 antibody status. Additionally, all household
members are asked to complete a daily questionnaire on
their state of health, whereabouts and social contacts
using an internet or a smartphone app (WebApp). Per-
sons who do not have a mobile phone or cannot operate
an App will be interviewed by phone. At least one
household member needs to agree to donate blood,
while other members can solely participate in the
questionnaires.
Inclusion criteria are:
 At the time of inclusion in the study (1st household
visit), at least one of the household members must
be ≥18 years and competent to provide written
informed consent.
 Sufficient command of German to understand the
participant information materials for the study and
to answer the questionnaires (Note: Due to the
urgency of the study, there is no possibility to
develop respondent information and multilingual
questionnaires or to recruit multilingual study
teams).
The households where residents are not present at the
time of the visit of one of the study teams and do not
call to the provided number in order to arrange a base-
line visit, individuals who do not give informed consent
or do not meet the inclusion criteria will be
 replaced by the next house on the route for single/
two-family houses
 replaced by the next apartment on the same floor in
the case of apartment buildings.
Non-response is recorded and taken into account in
the analysis of the response index. Where feasible, basic
information (age, sex, type of building) and reason of
non-participation are collected for non-responders in
order to assess representativeness of the study popula-
tion. In addition, participants’ socioeconomic status, mi-
grant status, sex, and percentage of households with
children and single households will be compared to the
official statistics of the selected constituencies and of all
Munich constituencies (Statistical Office Munich).
Field work
In order to pre-inform the population about the study
and thus, increase response, the study is announced in
the media and on a webpage (www.koco19.de) including
an information video (https://youtu.be/O_Qznp8FEA8).
In addition, field workers visit the selected households
before the start of the baseline study to introduce the
study, hand out a short leaflet and also the complete
information. In case of absence at the time of the infor-
mation visit, the teams leave information material in-
cluding a telephone number in order to schedule the
baseline visit. In the initial informative visit, teams are
accompanied by a police officer; this is considered help-
ful to enhance trust in the study in times were report-
edly fraudsters are taking advantage of the exceptional
situation.
Overall, at least 50 field workers working in 25 teams
of two are involved in the study. Each team is respon-
sible for 150 households in five constituencies. One field
worker is a medical student with prior, extensive train-
ing in infectious disease control, including blood sam-
pling and pharyngeal swabs in case participants have
symptoms suggestive for COVID-19 within 14-days
prior to this visit. The second field worker is responsible
for the informed consent and interviews. Teams of field
workers are carefully trained in study procedures, data
confidentiality, and infection protection and undergo a
proficiency test before initiating field work. During the
first field visits, they are accompanied by a senior med-
ical doctor of the Division of Infectious Diseases and
Tropical Medicine, LMU University Hospital Munich,
until the physician approves correct handling of all steps
of the field work. To further ensure the quality of field
work randomly selected households are called and asked
about the last study visit and potential problems. In
addition, teams will be repeatedly monitored by a senior
medical doctor throughout the study. To avoid infection
risks through public transport, all teams use rental cars
during the field work. This is also helpful for the teams
to be able to carry all the necessary material including
personal protective and hygiene equipment.
Study instruments: questionnaires
Wherever possible, questions were taken from pre-
existing validated questionnaire instruments [30–33]. As
it will be crucial to minimize attrition over time, we
minimized the number of questions without losing im-
portant information.
-Household questionnaire
The household questionnaire includes questions about
the living situation (type of housing, number of bed-
rooms, apartment size), number of inhabitants (includ-
ing date of birth and sex), highest level of education,
work situation, household income, second hand smoke
exposure, work of household members in potentially
high risk jobs for SARS-CoV-2 infections, past
pharyngeal swab testing for SARS-CoV-2 in household
members including test results.
-Individual baseline questionnaire
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At baseline, all participating household members are
asked about date of birth, sex, level of education, em-
ployment situation, smoking history, general health,
pregnancy, recent influenza vaccination, pre-existing
medical conditions, symptoms suggestive for COVID-19
in the 14 days prior to the study, past PCR testing of
nasopharyngeal samples for SARS-CoV-2 including test
result, use of respiratory masks, and work in a poten-
tially high risk job for SARS-CoV-2 infection.
-Diary
The daily diary includes items about symptoms sug-
gestive for COVID-19, social contacts, whereabouts and
use of public transport in the past 24 h. Further ques-
tions on e.g., the psychosocial and economic situation,
such as perceived health status, behavioral aspects, or
employment and income will be added over the time of
the study, and collected e.g. once a week.
Laboratory analyses
Samples will be analyzed and stored at the Division of
Infectious Diseases and Tropical Medicine, LMU Uni-
versity Hospital Munich.
First, blood is sampled in 2.7 ml EDTA containers and
thoroughly mixed. Samples are individually barcoded
and packed to be transported to the laboratory ion ice.
There, the samples are centrifuged to separate the cell
pellet from the remaining plasma. Cell pellets are frozen
at − 80 °C for further analysis, while the plasma is used
for ELISA analysis using a semi-automated robotic sys-
tem (Euroanalyzer I, Euroimmune, Lübeck, Germany).
Serology is performed primarily using the Anti-SARS-
Cov-2-ELISA IgG and IgA (Euroimmune, Lübeck,
Germany). The ELISA system has a combined sensitivity
of between 66.7% (< 10 days after onset of symptoms)
and 100% (> 10 days after onset of symptoms) according
to the manufacturer. Specificity is rated as 98.5%, tested
in larger cohorts of blood donors. The remaining plasma
is stored for further analysis or confirmatory testing e.g.
with virus neutralization as appropriate.
Pharyngeal swabs are taken using eSwab systems. The
samples are stored at 4 °C and immediately transported
to the laboratory. There, RNA extraction is performed.
Extracted RNA is divided to allow for cryo-conservation
at − 80 °C as well as for diagnostic RT-PCR for SARS-
CoV-2. The reserve sample will be used for virus se-
quence analysis to perform cluster and outbreak analysis
and to study within family transmission.
Statistical analysis
Sample size calculation
As an initial number of participants, 3000 households
with approx. 1.5 participants each were calculated.
Assuming that each person is included in the study with
the same probability, repeated drawing of 4500 from 1.5
million Munich residents will yield the 95% confidence
intervals listed in Table 1 for the subsequently assumed
prevalence of the total of reported and unreported infec-
tions in the baseline survey. The prevalence of con-
firmed cases was 0.3% on April 9th 2020 [34]. This
shows that the sample size is sufficient for an adequately
precise estimate of the actual sero-prevalence in the
baseline survey.
Data management
Data will be stored and handled at the Division of Infec-
tious Diseases and Tropical Medicine, LMU University
Hospital Munich. The pseudonymized databases will be
combined using a unique participant ID. Using the com-
bined raw data, a scripted routine analysis is used to
produce a daily update of descriptive and bivariate
prevalence and incidence data to generate a study “dash-
board” (The R project). Main outcome variables are the
prevalence and incidence of SARS-CoV-2 antibodies as
well as SARS-CoV-2 symptoms in the study population
and the dynamics thereof. Main exposure variables are
socio-economic factors, social contacts, city district as
well as the living situation. In addition, changes in the
non-pharmaceutical public health interventions will be
used as predictor of SARS-CoV-2 incidence.
Descriptive analyses
Initial descriptive data analyses will be weighted for clus-
ter sampling and include the following parameters:
 Description of basic data for responder and non-
responder households
 Socio-demographic data and known risk factors for
SARS-CoV-2 infection
 Baseline prevalence of SARS-CoV-2 sero-positivity
in the Munich general population stratified for a)
symptomatic and asymptomatic cases and b) cases
previously tested via PCR
 The temporal course of SARS-CoV-2 sero-positivity
in the Munich general population (point prevalence
and incidence) stratified for symptomatic and
asymptomatic subjects, and reported cases
 The daily prevalence and incidence of possible
COVID-19 symptoms in the study population
Bi-variable and multi-variable analyses
Subsequent bi- and multivariable analyses, taking cluster
sampling into account, will include the following
aspects:
○ Identification of risk factors for asymptomatic, mildly
symptomatic and severely symptomatic SARS-CoV-2
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infections (age, sex, socioeconomic status, occupation,
social contacts, district). Prevalence ratios are calcu-
lated for this purpose.
○ The temporal relationship of public health
interventions (school closures, etc.) with the incidence
of SARS-CoV-2 symptoms and changes in sero-
prevalence are analysed, e.g. by using mixed effect
models with a time varying covariate indicating the dif-
ferent intervention variables at different time points.
○ The effect of discontinuation of public health
interventions (school closures, etc.) are analysed
longitudinally, e.g. by mixed effect models.
○ The interaction between the epidemic and the
sociodemographic, economic, psychological variables,
and the interventions implemented to contain it, will be
analysed.
○ An algorithm for the most reliable prediction of
SARS-CoV-2 PCR positivity will be developed.
○ Geo-spatial modelling of exposures and outcome will
be performed.
In addition, the data is used to gain knowledge about
spread dynamics and to predict the further development
of the epidemic under different scenarios. Models used
for this purpose are developed throughout the course of
the study.
Discussion
The ongoing SARS-CoV-19 pandemic has changed daily
life globally to an extent unseen before. Due to the lack
of vaccinations and pharmacological treatment options,
it was predicted that not taking public health action will
result in an overload of healthcare systems in most
countries and a mortality of millions in the global popu-
lation [25]. The public health interventions that have
been recently implemented by most countries have a
huge impact on the economy and most likely, also on
health and well-being of the global population. There-
fore, to further understand the dynamics of the disease,
population-based representative household studies might
be helpful and needed, in order to reliably estimate the
total number of previously infected individuals (with and
without symptoms), who are – hopefully – resistant to
infection for an extended period of time.
The study presented here will provide a first estimate
of the prevalence and incidence of sero-positivity in the
Munich population. Although not generalizable on a
global scale, this will give first insights about the propor-
tion of asymptomatic and mildly symptomatic carriers of
SARS-CoV-2 in comparison to the number of those
tested. It will also help to identify risk factors for infec-
tion, course of disease and effectiveness and efficiency of
the public health measures.
Our study has limitations. In the last years, willingness
to participate in population-based studies went down
considerably [35, 36]. Low response might affect repre-
sentativeness of the study population, which in turn
might have an effect on the generalizability of the preva-
lence of positive antibody results to the Munich source
population. However, it is unlikely that participation will
depend on sero-positivity of antibody results as antibody
status is unknown prior to inclusion in the study. In
addition, the research topic is of uppermost interest for
many citizens in the current situation, therefore re-
sponse is expected to be higher in KoCo19 than in other
studies. During the first recruitment days, an overall re-
sponse of close to 50% was reached, this provides evi-
dence for the aforementioned hypothesis. Response will
be increased by revisiting households which did not
open the door at the first visit. For the associations
under study, representativeness is of less concern [37].
However, we might not be able to reach high response es-
pecially in specific groups of the target population, e.g.
subjects with migration background as they are generally
harder to reach in epidemiological studies [38] and be-
cause time constraints impede the development of study
documents in other languages than German at the initi-
ation of the study. Likewise, the spread of SARS-CoV-2
varies locally and depends on several factors, such as the
time course of the infection in the respective region, the
Table 1 95% Confidence Intervals of SARS-CoV-2 prevalence in the study population by assumed true prevalence in the Munich
population (The R Project)
Assumed true prevalence of SARS-CoV-2 seropositive residents of
Munich
(1.5 million inhabitants)
95% Confidence Interval of SARS-CoV-2 seropositive participants in
KoCo19
(N=4,500)
0.5% 0.31% - 0.71%
1% 0.71% - 1.29%
5% 4.38% - 5.64%
10% 9.13% - 10.89%
20% 18.84% - 21.18%
30% 28.67% - 31.31%
50% 48.56% - 51.47%
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population density and age distribution of the population,
the available capacities and the applied countermeasures.
Therefore, prevalence and incidence results obtained in
this study locally might not be easily generalizable to other
cities, regions or countries. Losses-to-follow up will likely
occur especially when public health interventions are re-
duced or become less restrictive and the public attention
focuses less on the pandemic. However, as long as these
missing data can be assumed to be missing at random
multiple imputation can account for attrition [39].
With respect to reporting bias, one may assume that
participants are more likely to over-report symptoms
which will result in an overestimation of the symptom
prevalence. In order to minimize other forms of report-
ing bias we use as many items from validated question-
naire instruments as possible. In addition, all items were
carefully checked by several members of the KoCo-19
team for their face validity. Questionnaires, especially
the daily diary, were kept as short as possible. Therefore,
the study might not be able to answer specific questions
in favour of more valid answers and low attrition rate
over time. For such aspects, case-control studies, poten-
tially nested in the current study, could be performed.
For ethical reasons, participants will receive their SARS-
CoV-2 antibody status after each blood sampling. This
might influence their subsequent behaviour, especially
when antibody status is positive.
To minimize social desirability bias, questionnaires are
web-based and are completed by the participants them-
selves. However, because not all participants might have
web-access and especially older participants might not
have the necessary internet competencies, a telephone
interview is also offered. Type of response (online or
interview) is recorded so that systematic differences in
response can be accounted for. We are not able to in-
clude children under the age of 14 years from the begin-
ning mainly due to ethical concerns regarding the
venous blood sampling by a medical student. Over the
course of the study development of other test methods
might allow the inclusion of this important part of the
population.
Random route recruitment is a feasible way of recruit-
ment where population lists do not exist or are hard to
obtain. It has been applied by the WHO in various vac-
cination studies since the 1980s, was modified over time
and it is also used in large scale community surveys such
as the European Working Condition Survey [29, 40].
The alternative approach, sampling via the Munich
population registry, would have taken more time due to
the formal requirements and thus would have slowed
down the start of the study. As we apply a cluster sam-
pling approach (100 out of 755 constituencies) and in-
clude more than one person per household and more
than one subject per apartment building, clustering has
to be taken into account in the statistical analyses. Using
constituencies made inclusion of 3000 households and
the follow-up visits within six weeks feasible. Inclusion
of more than one household member and one household
per floor will help us to better understand the spread of
SARS-CoV-2 within households and apartment build-
ings. In addition, inclusion of more than one household
per apartment building takes into account that larger
number of inhabitants live in apartment buildings, than
in one- or two-family houses, which would otherwise
have been overrepresented.
The sample size calculation reported here did not take
clustering into account. This was due to the fact that the
prevalence of SARS-CoV-2 within clusters (household,
apartment building, constituency) is so far unknown.
Taking a more conservative approach of considering
only 3000 participants (= number of households) instead
of 4500 participants, the 95% Confidence Interval for a
given prevalence of 0.5% (50%) would increase from
0.3–0.7% (49–51%) to 0.3–0.8% (48–52%). Thus,
changes are minimal and we therefore conclude that our
prevalence estimates will be precise.
Currently, there is only a limited number of reliable
serologic tests available. By using the – to our know-
ledge – best currently available serology test system with
IVD certification in the study, the number of valid re-
sults will be maximized as compared to other less ma-
ture testing systems. Still, with very low sero-prevalence,
the false positive rates in the population might be in the
range of the test-background. All currently performed
studies face this limitation. However, by repeating visits,
the seroconversions will be confirmed, thus offering
much better data than mere sero-prevalence data. In
addition, it has not yet been established that sero-
positivity in ELISA reliably corresponds to immunity.
Thus further testing such as virus neutralization is per-
formed for questionable cases.
As serology only allows the detection of infection in
retrospect, the pharyngeal swab is essential to pick up
acute infections. This also allows to detect subjects with
symptomatic disease who possibly never develop positive
serology; although it is currently believed that most pa-
tients will develop positive serology within 10 days after
onset of symptoms. Besides, the swab can be used to ex-
tract viral RNA and used for sequencing, offering further
information about transmission dynamics within house-
holds, quarters or even worldwide.
In a pandemic situation, it would neither be ethical
nor feasible to use medical doctors for epidemiological
field work as they are needed for clinical service. There-
fore, experienced medical students together with stu-
dents of other subjects perform the field work of this
study. The medical students involved are not removed
from other important tasks during the pandemic. Ethical
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considerations are also relevant for the use of personal
protective equipment in this study. Currently, personal
protective equipment is available at Munich hospitals.
Its’ availability is being re-evaluated regularly over the
duration of the field work and the demand for personal
protective equipment in clinical services will always have
priority.
Conclusion
KoCo19 is a unique possibility to obtain more reliable
estimates of the spread of SARS-CoV-2 in the general
population and to better understand the dynamics of
COVID-19. Although a single epidemiologic cohort
study in one city will not be able to answer all questions
related to SARS-CoV-2; it will provide an important epi-
demiological basis for our understanding of the epi-
demic, and might serve as a blueprint for similar studies.
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